MRSN / Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d more_horizontal

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to t more_horizontal

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to t more_horizontal

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compa more_horizontal

San Francisco-based investment firm, EcoR1 Capital, LLC (Trades, Portfolio), recently executed a significant transaction involving the acquisition of more_horizontal

Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinu more_horizontal

Mersana Therapeutics (NASDAQ:MRSN) stock plummeted more than 60% on Thursday after the clinical-stage biopharmaceutical company announced that the Foo more_horizontal

Mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its ovarian cancer drug studi more_horizontal